Effects

• Strontium ranelate works, according to studies made at Johns Hopkins, in two ways: by slowing down the process of the breakdown (resorption) of bone, and also by contributing to the growth of new bone matter.
  
  

Features

• This medication has been shown to reduce the risks of hip and non-vertebral fractures, according to Johns Hopkins and to researchers like V. Rabenda and J.Y. Reginster of the Department of Public Health, Epidemiology and Health Economics at the University of Liege, Belgium.
  
  

Significance

• Risk of fractures has been reduced, according to Johns Hopkins, by 16 percent (for non-vertebral) to 19 percent (hip, pelvis, rib, wrist) in tested women, and by up to 36 percent in women in high-risk groups for fracture.
  
  

Types

• Where it is available, strontium ranelate is marketed as Protelos, according to Johns Hopkins.
  
  

Geography

• The Food and Drug Administration (FDA) has not yet approved strontium ranelate as an osteoporosis treatment in the United States. It is already in use in countries like the UK, according to Johns Hopkins.